Protocol Ledger

NCT05537766 · Phase II · TERMINATED

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

Interventional Phase II clinical trial protocol NCT05537766 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-01 Enrollment: 19 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05537766
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)19 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05537766
Protocol FieldVerified Registry Value
NCT IdentifierNCT05537766
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment19 participants (ACTUAL)
Registered Start Date2022-11-01
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI